|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||41.50 - 41.60|
|52 Week Range||31.55 - 41.71|
|Beta (3Y Monthly)||0.29|
|PE Ratio (TTM)||8.53|
|Forward Dividend & Yield||1.71 (4.12%)|
|1y Target Est||29.80|
Moody's Investors Service has affirmed Shandong Ruyi Technology Group Co., Ltd.'s B2 corporate family rating (CFR) and the B3 rating on the senior unsecured notes issued by Prime Bloom Holdings Limited and guaranteed by Shandong Ruyi. "The negative outlook reflects our concern over Shandong Ruyi's deleveraging trends because of its high growth strategy and strong acquisitive appetite," says Chenyi Lu, a Moody's Vice President and Senior Credit Officer. Moody's expects Shandong Ruyi's debt leverage, as measured by adjusted debt/EBITDA, to recover to 7.0x-7.5x over the next 12-18 months from 8.5x in 2018, driven by improved EBITDA and partially offset by an increase in debt to support its investments and working capital needs.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of ITOCHU Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
It's been a volatile up and down ride, fittingly enough, for shareholders of sportswear maker Descente 8114 . It's rare to see any shareholder activism in Japan. Descente shares have ascended 54.5% since the bidding began.
BrainsWay Ltd. (BRIN.TA), a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Deep TMS System has been approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of patients suffering from Major Depressive Disorder (MDD) who did not benefit from previous antidepressants. The PMDA approval was obtained in collaboration with BrainsWay’s exclusive distributor in Japan, Century Medical, Inc. (CMI), an ITOCHU Group company.
Jan 14 (Reuters) - CITIC Ltd: * CITIC WILL ESTABLISH AN INVESTMENT FUND IN SINGAPORE WITH JAPANESE TRADING HOUSE ITOCHU FOR BUILDING DATA CENTERS IN CHINA - NIKKEI * FUND WILL START OUT WITH INVESTMENTS ...
Jan 2 (Reuters) - Shandong Longda Meat Foodstuff Co Ltd : * SAYS SHAREHOLDER ITOCHU (CHINA) PLANS TO UNLOAD UP TO 2.1 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2GSyhQx ...
Don Quijote Holdings Co Ltd: * ITOCHU CORP - ANNOUNCES RESULTS OF TENDER OFFER FOR SHARES IN DON QUIJOTE BY SUBSIDIARY FAMILYMART UNY Source text for Eikon: Further company coverage:
Japan's Itochu Corp on Friday booked a $1.3 billion loss on its investment in China's CITIC Ltd, blaming trade tensions between China and the United States for the writedown on its biggest corporate transaction. The announcement came while releasing earnings as Japanese trading houses sounded a warning about the Chinese economy and the impact of Sino-U.S. trade friction. "In light of the current status of the trade conflicts between the U.S. and China, Itochu considered the uncertainty of the economic outlook in China, where CITIC, conducts its primary business activities, was increasing," the trading firm said.
Moody's Investors Service ("Moody's") has today changed the outlook on the backed senior secured rating of the GBP40 million index-linked notes due in 2041 (the notes) issued by Bristol Water plc (Bristol Water) to negative from stable. The rating action follows Bristol Water's business plan submission on 3rd September 2018, which sets out the company's proposed investment strategy and financial policy for the next five-year regulatory period commencing in April 2020, in light of what will likely be a challenging price review.